UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of August 2026
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720,
333-207933, 333-215983,
333-222891, 333-233267
and 333-265866.
The following exhibit is attached:
| 99.1 |
|
Kamada to Announce Second Quarter and First Half Ended June 30, 2026
Financial Results on August 12, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 5, 2026 |
KAMADA LTD. |
| |
|
| |
By: |
/s/ Nir Livneh |
| |
|
Nir Livneh
Vice President General Counsel and
Corporate Secretary |
EXHIBIT INDEX
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1 |
|
Kamada to Announce Second Quarter and First Half Ended June 30, 2026
Financial Results on August 12, 2026 |
Exhibit 99.1
Kamada to Announce Second Quarter and First
Half Ended June 30, 2026 Financial Results on August 12, 2026
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, NJ – August
5, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated
for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial
results for the second quarter and first half ended June 30, 2026, prior to the open of the U.S. financial markets on Wednesday, August
12, 2026.
Kamada
management will host an investment community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these
results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from
within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13761830. The call will be
webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1770235&tp_key=a29c72f53b.
About Kamada
Kamada Ltd. (the “Company”) is a global
biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling
shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving
profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment
in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived
products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based
anti-snake venom products. Second, distribution of third-parties’ pharmaceutical products in Israel & the MENA region through in-licensing
partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations
to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing
demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States,
in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing
and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its
financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing,
research and development expertise to advance the development and commercialization of additional product candidates, targeting areas
of significant unmet medical need.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
